BioSpace News Archive

Drug Development

Nimbus Therapeutics Presents New Data on Oral Allosteric TYK2 Inhibitor at American Chemical Society Meeting

Nimbus Therapeutics today presented research describing the chemical structure of NDI-034858, the company’s investigational oral allosteric TYK2 (tyrosine kinase 2) inhibitor now in two Phase 2b clinical studies for moderate-to-severe plaque psoriasis.

August 24, 2022
·
3 min read
BioCapital

AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022

AstraZeneca will present new data supporting its ambition to redefine cancer care at the European Society for Medical Oncology (ESMO) Congress 2022, September 9 – 13, 2022.

August 24, 2022
·
33 min read
Drug Development

Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms

Ainos, Inc. today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA®, for treatment of mild symptoms related to COVID-19.

August 24, 2022
·
5 min read
Genetown

Repligen To Host Investor Day 2022

Repligen Corporation today announced that it will host “Repligen Investor Day 2022” on Tuesday, September 20. The live event will take place at the Nasdaq MarketSite in New York City from 8:20 to 11:30 a.m. EDT.

August 24, 2022
·
2 min read
Drug Development

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

SciSparc Ltd. today announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction.

August 24, 2022
·
4 min read
Pharm Country

Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release

Trevi Therapeutics, Inc. today announced two late-breaking abstracts were accepted for presentation at upcoming fall medical conferences.

August 24, 2022
·
9 min read
Drug Development

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease

Annovis Bio, Inc. announced today that the first patient in the Phase 3 clinical trial evaluating buntanetap in early Parkinson’s Disease (PD) has been dosed.

August 24, 2022
·
4 min read
Business

Think Research Announces Date of Second Quarter 2022 Earnings Release and Conference Call Details

Think Research Corporation today announced that it will release its financial results for the three months ended June 30, 2022 before the market opens on August 29, 2022.

August 24, 2022
·
2 min read
Business

Make-A-Wish® America Announces the Appointment of Leslie Motter as President and CEO

Make-A-Wish America today announced that the board of directors has appointed Leslie Motter as the organization’s new president and CEO, as current President and CEO Richard Davis steps down to begin his retirement.

August 24, 2022
·
3 min read
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

BetterLife Pharma Inc., is an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders.

August 24, 2022
·
4 min read